Beijing Hotgen Biotech Co.,Ltd(688068.SH) subsidiary SGC001 innovative drug "expected severe acute pancreatitis" indication Phase II clinical study completed first subject enrollment and dosing

Beijing Hotgen Biotech Co.,Ltd(688068.SH) announced that recently, the Phase II clinical study of the innovative drug SGC001 injection for the "expected severe acute pancreatitis" indication, independently developed by its controlling subsidiary Beijing Shunjing Biopharmaceutical Technology Co., Ltd. ("Shunjing Pharma"), completed first subject enrollment and dosing. This time, the Phase II clinical study of the SGC001 targeted antibody investigational drug, jointly developed by Shunjing Pharma and Beijing Institute of Heart, Lung and Blood Vessel Diseases of Anzhen Hospital, for the newly added "expected severe acute pancreatitis" indication completed first subject enrollment and dosing, marking that this heavyweight candidate drug with potential First-in-Class (FIC) value has entered the multi-indication clinical development stage. This is another important progress achieved by SGC001 following its advancement of clinical research in the field of acute myocardial infarction.